

To: (10)(2e) | (10)(2e) @rivm.nl]
Cc: (10)(2e) | (10)(2e) @rivm.nl]; (10)(2e) | (10)(2e) @rivm.nl]; (10)(2e) | (10)(2e) @rivm.nl]; (10)(2e)
 (10)(2e) | (10)(2e) @rivm.nl]
From: (10)(2e)
Sent: Tue 9/8/2020 7:50:35 PM
Subject: FW: Invitation to scientific meeting with Moderna
Received: Tue 9/8/2020 7:50:35 PM
 (10)(2e) - [Invitation to scientific meeting with Moderna.pdf](#)
[Elderly Ph 1 Data - Final \(08.26.20\) 3pm PDF-compressed for email.pdf](#)

Ha (10)(2e)

We hadden het gisteren al over het organiseren van wetenschappelijke updates voor de kandidaat vaccins. Alleen bedachten wij dat we wat meer klinische data af wilden wachten. Misschien toch wel handig om nu al kennis te maken met het vaccin dat we mogelijk begin 2021 (vertrouwelijk) al krijgen? In ieder geval hebben we hier een handige contactpersoon*. Even afstemmen wie reageert en wanneer we ze uitnodigen.

Vriendelijke groet,

(10)(2e)

From: (10)(2e) | (10)(2e) @modernatx.com> **On Behalf Of** (10)(2e)
Sent: dinsdag 8 september 2020 20:35
To: (10)(2e) <(10)(2e)@rivm.nl>
Cc: (10)(2e) <(10)(2e)@rivm.nl>
Subject: Invitation to scientific meeting with Moderna

Dear Mr. (10)(2e)

I hope this finds you well.

I am pleased to extend the attached invitation to you for a meeting at your convenience as we reach a number of crucial milestones in the development of our vaccine candidate mRNA-1273 furthering our goal of bringing mRNA technology to the benefit of European and global citizens in the fight against COVID-19.

I would like to offer our availability to meet with you and your team, to share insights into the science and data behind mRNA-1273, hear your views and answer any questions you may have regarding the role our vaccine candidate could play in a portfolio of solutions to address the current crisis.

The Moderna team and I very much look forward to the opportunity to bring our mRNA technology to Europe.

Thank you in advance for your time and consideration.

Kind Regards,



 Please consider the environment before printing this email

Confidentiality notice and disclaimer: The information in this message and any attachments is intended for the exclusive use of the addressee(s), is confidential and may be privileged or otherwise protected from disclosure. Any review, retransmission, dissemination or other use of, or taking of any action in reliance upon, of any such information by persons or entities other than the intended addressee(s) is prohibited. If you have received this message in error and are not the intended addressee, please notify the sender immediately and delete this message and any attachments from your system without reading or disclosing them. If you are not the intended addressee, be advised that any use of the information in this message and any attachment is prohibited and may be unlawful, and you must not copy this message or attachment or disclose the contents to any other person.